Regenerative medicine research efforts are set to strengthen in Australia with the recent announcement between Melbourne’s Monash University and leading US biomedical institution, MDI Biological Laboratory.

As marketers and CX leaders seem reluctant to totally dive into generative AI, usage skyrockets.

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy  News-Medical.Net

This is fantastic news that will hopefully turn into a treatment for people with spinal cord injuries and other nerve injuries.

A self-assembling gel injected at the site of spinal cord injuries in paralysed mice has enabled them to walk again after four weeks.

The gel mimics the matrix that is normally found around cells, providing a scaffold that helps cells to grow. It also provides signals that stimulate nerve regeneration.

Samuel Stupp at Northwestern University in Chicago and his colleagues created a material made of protein units, called monomers, that self-assemble into long chains, called supramolecular fibrils, in water.

When they were injected into the spinal cords of mice that were paralysed in the hind legs, these fibrils formed a gel at the injury site.

The researchers injected 76 paralysed mice with either the fibrils or a sham treatment made of salt solution, a day after the initial injury. They found that the gel enabled paralysed mice to walk by four weeks after the injection, whereas mice given the placebo didn't regain the ability to walk.

The team found that the gel helped regenerate the severed ends of neurons and reduced the amount of scar tissue at the injury site, which usually forms a barrier to regeneration. The gel also enhanced blood vessel growth, which provided more nutrients to the spinal cord cells.

PRZOOM - Newswire (press release) - Tue, 12 Nov 2024 00:00:00 -0500, Cary NC United States - Strategic move reinforces SAS leadership in data and AI, enhancing customer innovation and data security - Hazy.com / SAS.com

Today, SAP SE announced the next step in its long-standing partnership with Microsoft, using the latest in enterprise-ready generative AI innovation to help solve customers' most fundamental business challenges. The companies will collaborate on integrating SAPamp;reg;SuccessFactorsamp;reg; solutions with Microsoft 365 Copilot and Copilot in Viva Learning, as well as Microsoft's AzureOpenAI Service to access powerful language models that analyze and generate natural language. The integrations will enable new experiences designed to improve how organizations attract, retain and skill their people.

Paula MacDowell, Kristin Moskalyk, Katrina Korchinski, Dirk Morrison, Canadian Journal of Learning and Technology, Nov 13, 2024

This paper reports on a process where thirty-five teachers enrolled in an elective three-credit multimedia design course "engaged in experiential activities focussed on developing artificial intelligence (AI) literacy, alongside a collaborative assignment to co-author an open-access textbook, Teaching and Creating With Generative Artificial Intelligence." In the process, "the Student Artificial Intelligence Literacy (SAIL) framework was developed (illustrated)." The paper concludes with the usual recommendations ('do no harm', 'develop communication skills', etc.). Each participant wrote a chapter, though a common template was used. I very much like the idea of producing a useful open resource as part of class activities. Oddly, the article doesn't provide a link to the textbook, but I found it here. It's a nice selection of 'how-to' articles that readers, I think, will find useful. One chapter (chapter 20 1/2?) is missing.

Aim/Purpose: In a world of rapidly expanding complexity and exponentially increasing data availability, IT-based knowledge management tools will be needed to manage and curate available information. This paper looks at a particular tool architecture that has been previously proposed: The Personal Knowledge Management System (PKMS). The specific focus is on how the proposed architecture conforms to design science principles that relate to how it is likely to evolve. Background: We first introduce some recent informing science and design science research frameworks, then examine how the PKMS architecture would conform to these. Methodology: The approach taken is conceptual analysis. Contribution: The analysis provides a clearer understanding of how the proposed PKMS would serve the diverse-client ambiguous-target (DCAT) informing scenario and how it could be expected to evolve. Findings: We demonstrate how the PKMS informing architecture can be characterized as a “social machine” that appears to conform to a number of principles that would facilitate its long-term evolution. Future Research: The example provided by the paper could serve as a model future research seeking to integrate design science and informing science in the study of IT artefacts.

With the growth of video content across various industries, Lumeo said the ability to efficiently analyze and derive insights from this data is crucial.

Prepared Foods explores the growing and dynamic topic of regenerative agriculture in a discussion with Ryan Slabaugh, founder of Think Regeneration.

The company has a broad and ambitious approach to expanding regenerative agriculture, working with partners spanning the value chain, connecting farmers to end customers, technology providers and technical experts.

Implementing this change across its entire beef hot dog portfolio is expected to contribute to the regeneration of six million acres of grasslands, which could increase the current regenerative acreage of Applegate suppliers by more than 2,200%.

QUINN announced its participation in the Soil Carbon Initiative (SCI). Since 2020, QUINN has worked with Nebraska sorghum grower Steve Tucker, an SCI farmer partner, as he transitions to regenerative practices. Sorghum, a nutrient-dense and inherently sustainable crop, has been a crucial ingredient for Quinn’s supply chain since the company debuted whole-grain, gluten-free pretzels in 2016.

The investment will enable Lotus Foods to further scale its business by deepening investments along its value chain, from sourcing new global rice cultivation communities to growing and diversifying its customer base.

Dr. Bronner’s Regenerative Organic Certified Salted Dark Magic All-One Chocolate goes beyond USDA Organic and Fair Trade standards, demonstrating that regenerative organic agriculture can be practiced at the scale needed to meet global market demands. 

These partnerships aim to encourage wheat, corn and rice farmers in select regions of North America to implement regenerative agriculture practices, contributing to scope 3 carbon reductions.

The lab will be used for the research and development of regenerative coffee with 100% electric roasters.

Source: Streetwise Reports 10/28/2024

Sernova Corp. (SVA:TSX.V; SEOVF:OTCQB; PSH:XERTA) and its Cell Pouch technology could be the solution to existing challenges involving the delivery of medical treatments to patients, such as the ones described here.

Diabetic patients in resource-limited settings are having to revert back to one of the less favored, alternative ways to take insulin, via syringes or glass vials, because Danish pharmaceutical company, Novo Nordisk A/S (NVO:NYSE), will stop making its insulin pens, The Guardian reported. Patients generally prefer this method for dosing themselves with insulin, as shown in a 2024 survey, because it is more convenient and more accurate.

Type 1 diabetic patients already are being impacted as Novo stopped supplying its insulin pens to certain regions, South Africa for instance. Patients there have switched back to using glass vials.

In a second situation, Novo Nordisk is working to bring stem cell-based therapies to patients more efficiently and, in seeking a solution, formed a partnership with Evotec SE (EVO:NASDAQ) to develop technologies that will achieve this, noted Evotec is a Germany-based global biotech firm with its own cell therapy and partnered cell types all in preclinical development for various indications, including diabetes, oncology, cardiology, and ophthalmology.

Per the agreement, Novo Nordisk is to provide research and development funding and potentially monetary incentives to Evotec, and Evotec is to develop the desired new technologies. Novo has the option to obtain exclusive rights to use, in a predefined medical indication, the product(s) born out of this collaboration agreement. Novo's areas of focus, along with diabetes, are cardiovascular diseases, rare diseases, growth hormone-related diseases, hemophilia, nonalcoholic steatohepatitis, and weight management.

Safe, Effective Therapeutic Cell Delivery

Sernova Corp.'s Cell Pouch is a vehicle for delivering various types of therapeutic cells to patients, such as donor islet cells to insulin-dependent diabetics.

When used, the Cell Pouch's containment channels are filled with the appropriate therapeutic cells, and then the device is implanted in the patient. In situ, the cells release therapeutic proteins or hormones the patient's body completely or partially lacks. The device creates a vascularized, organ-like environment that protects the therapeutic cells from immune system attacks, keeping them alive and functioning.

"The Cell Pouch is the most advanced encapsulation device in development," Ventum Capital Markets Analyst Stefan Quenneville wrote in a Sept. 12 research report.

Sernova is testing its Cell Pouch in the clinic, specifically in Type 1 diabetes. In its ongoing Phase 1/2 study, the Canadian company is evaluating the treatment of insulin-dependent diabetes with donor islets implanted via the Cell Pouch, with added immunosuppression therapy. Study data so far have shown the Cell Pouch to be safe and well tolerated and the treatment, effective, reported Dr. Joseph Pantginis, analyst at H.C. Wainwright & Co., in a Sept. 12 research report.

Seven patients, all six of Cohort A and one in Cohort B, achieved sustained insulin independence, between 5.5 and 50 months in duration, free of hypoglycemic episodes. Their blood sugar levels were controlled in the nondiabetic range (i.e.,) HbA1c less than 6.5%.

"The Cell Pouch is the most advanced encapsulation device in development," Ventum Capital Markets Analyst Stefan Quenneville wrote.

A Cell Pouch removed from one of the study patients showed it still contained functioning insulin, glucagon, and somatostatin-producing cells. No evidence was seen of detrimental fibrotic tissue, too many T-cells, material degradation, or changes in the device architecture.

"We believe the impressive response rates and observed durability support Sernova's strategy and justify further investigation while positioning the technology for potential commercial success," noted Pantginis.

The results add to an expanding collection of evidence that the Cell Pouch is functioning as it should. The data also support the "impressive" results already reported from this study and help derisk future related trials.

"If Sernova is successful in bringing its functional cure for insulin-dependent diabetes to the stage where it can go into commercial production, the global market for it will be massive," wrote Technical Analyst Clive Maund in a Sept. 16 note.

In another of its programs, Sernova, in collaboration with Evotec, is developing an implantable off-the-shelf, induced pluripotent stem cell (iPSC)-based islet replacement therapy, Maund reported.

"This partnership provides Sernova a potentially unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (Type 1 and Type 2)," he added.

This partnership was announced on May 17, 2022. You can read more about it in the press release here.

Market Growth Predicted to 2030

The global live cell encapsulation market, encompassing drug delivery, regenerative medicine and cell transplantation, is expected to continue growing through at least 2030, according to Grand View Research. The market's value, US$210.7 million in 2022, is forecasted to increase at a 3.97% compound annual growth rate between that year and 2030.

"If Sernova is successful in bringing its functional cure for insulin-dependent diabetes to the stage where it can go into commercial production, the global market for it will be massive," wrote Technical Analyst Clive Maund.

Along with diabetes, live cell encapsulation is being used to treat neurological disorders like Parkinson's disease, The market research firm noted. Further, it has been proven to be a suitable way to deliver treatment for other types of diseases, including cancer, anemia, heart failure and more.

Several factors are expected to keep driving market growth during the forecast period, Grand View noted. A significant one is the increasing use of live cell encapsulation in regenerative medicine to replace disease or damaged tissues. A related contributor is rising public and private funding and investments in cell and gene therapies.

The advantages of live cell encapsulation in controlled drug delivery are boosting the market, too. They include enhanced therapeutic effects, lowered drug dose, reduced cytotoxicity, improved patient convenience and better patient compliance.

Novel new products and technological advancements are expected to add value to the market as well.

The Catalysts: Progress With Programs

Various potential stock-moving events are slated for Sernova, according to its September 2024 Corporate Presentation.

Two catalysts are expected by Sernova in 2025, related to the company's ongoing Phase 1/2 clinical trial in Type 1 diabetes. One is results for the remaining Cohort B patients. The other is commencement of Cohort C, who will receive, along with the islet cells, an optimized immune suppression regimen.

Several analysts are bullish on Sernova. One of them is Loe, who rates it as a Speculative Buy. His price target on the life sciences firm implies a 455% return from its current share price.

Next year, Sernova plans to start a Phase 1/2 trial of the regeneratively produced islet cells to result from its partnership with Evotec, delivered via the Cell Pouch to Type 1 diabetes patients.

Other catalysts are expected to come as a result of Sernova advancing its preclinical programs. One is a personalized treatment with patient corrected cells via Cell Pouch for hypothyroidism. Another is a Cell Pouch-delivered, ex vivo lentiviral factor VIII gene therapy for hemophilia, being developed in partnership with the European Haemacure Consortium.

Also, through partnerships, Sernova is developing technologies that would eliminate the need for concurrent immunosuppression during Cell Pouch-delivered cell treatment, a "blue sky objective," Douglas Loe, a Leede Financial Inc. analyst, noted in a Sept. 12 research report.

"Any advances in this regard could be incorporated into future Cell Pouch studies," he wrote. "We do not consider the need for such therapy to be relevant to Cell Pouch function itself."

Analyst: Company is "Very Undervalued"

Several analysts are bullish on Sernova. One of them is Loe, who rates it as a Speculative Buy. His price target on the life sciences firm implies a 455% return from its current share price.

According to H.C. Wainwright's Pantginis, the deepening responses of Type 1 diabetes patients in its Phase 1/2 trial continue to "crystallize Sernova stock's possible upside." The upside reflected in Pantginis' price target is 2,122%. The analyst recommends the company as a Buy.

Ventum's Quenneville also has a Buy on Sernova, and his target price reflects an 826% return on investment. In his report, the analyst highlighted the impressive efficacy and tolerability of the Cell Pouch up to five years post-implantation, as shown in the Phase 1/2 clinical trial data.

"This represents the longest-lasting implanted encapsulation device containing functioning islets without fibrosis," Quenneville wrote.

According to Technical Analyst Maund, Sernova is "very undervalued here given its huge potential" in the Type 1 diabetes market, as indicated on the stock charts. The fundamental outlook for the company is improving, and evidence is strong that a reversal to the upside may be happening. SVA may appreciate significantly soon. [OWNERSHIP_CHART-4790]

"Sernova is therefore viewed as a good stock to accumulate in this area, between the current price and recent lows," Maund wrote on Sept. 16. At that time, Sernova's share price was about the same as it is now.

Ownership and Share Structure

According to Refinitiv, about 12.96% of the company is held by insiders and management, and 0.05% by institutions. The rest is retail.

Top shareholders include Tomas Angel with 4.91%, Director Steven Sangha with 4.27%, Betty Anne Millar with 1.32%, Brett Alexander Whalen with 0.87%, and Garry Deol with 0.77%.

Its market cap is CA$83 M. Its 52-week range is CA$0.20−0.82 per share.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Sernova Corp. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Sernova Corp.
3. Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
4. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

( Companies Mentioned: SVA:TSX.V;SEOVF:OTCQB;PSH:XERTA, )

Source: Dr. Jonathan Aschoff 11/07/2024

BioRestorative Therapies Inc. (BRTX:OTCBB) received a provisional license from the New York State Department of Health (NYSDOH) to process allogeneic donor tissue for various cells, like stem, to be isolated, expanded, and cryopreserved for medical research, reported MKM analyst Dr. Jonathan Aschoff in a Nov. 5 research note.

The biotech develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells.

1,100% Upside Implied

Aschoff reiterated Roth's US$18 per share target price on the biotech, trading at the time of the report at about US$1.50 per share, the analyst noted. These figures reflect a potential return for investors of 1,100%.

BioRestorative Therapeutics remains a Buy.

Sources of Revenue

Aschoff discussed how BioRestorative can generate revenue. This new license is the second from NYSDOH that the biotech holds. The previous one allows it to process autologous mesenchymal stem cells, in other words, act as a tissue bank.

The U.S.-based biotech now may capitalize on its Current Good Manufacturing Practices capabilities and process, bank and distribute clinical-grade allogeneic biologics. This revenue generation would better position the biotech financially, "allowing it to reduce cash burn and dependence on equity markets," wrote Aschoff.

Another source of revenue for BioTherapeutics is from its supply agreement with Cartessa Aesthetics LLC signed earlier in 2024. Per the five-year agreement, BioTherapeutics will supply Cartessa with a preset minimum quantity of finished vials of the aesthetic company's initial cell-based biologic commercial product each year. This product, intended to reduce the appearance of fine lines and wrinkles, will be sold under the Chronos ExoCR mark. Cartessa, on the other hand, will give BioTherapeutics access to its marketing and distribution capabilities to get its technologies to aesthetic providers.

The biotech may expand the Cartessa agreement into a broader offering of biocosmeceuticals and therapeutics if future clinical trials support their approval by the U.S. Food and Drug Administration. This expansion would transform the partnership into "a vertically integrated biocosmeceutical platform," Aschoff wrote.

Clinical Trial Catalyst

Meanwhile, Aschoff reported, BioRestorative will continue its Phase 2 clinical evaluation of its novel back pain treatment, BRTX-100, in patients with chronic lumbar disc degeneration.

Preliminary results from this clinical trial are expected in late Q4/24 or early Q1/25.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
2. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for Roth MKM, BioRestorative Therapies Inc., November 5, 2024

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Disclosures: Within the last twelve months, ROTH Capital Partners, or an affiliate to ROTH Capital Partners, has received compensation for investment banking services from BioRestorative Therapies, Inc.. ROTH makes a market in shares of BioRestorative Therapies, Inc. and as such, buys and sells from customers on a principal basis. Shares of BioRestorative Therapies, Inc. may be subject to the Securities and Exchange Commission's Penny Stock Rules, which may set forth sales practice requirements for certain low-priced securities.

ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months. The material, information and facts discussed in this report other than the information regarding ROTH Capital Partners, LLC and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This report should not be used as a complete analysis of the company, industry or security discussed in the report. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this report are subject to change without notice. An investment in the stock may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, an investment in the stock may involve a high degree of risk and may not be suitable for all investors. No part of this report may be reproduced in any form without the express written permission of ROTH. Copyright 2024. Member: FINRA/SIPC.

( Companies Mentioned: BRTX:OTCBB, )

Many business users have approached generative AI technology more cautiously because it can make up untrue facts and be tricked into saying unsettling things. Oracle's human resources software is used by big businesses for hiring new employees and providing performance evaluations, among other things. Oracle will put a button on many of the fields in the software that will automatically generate draft text for things like job listings or performance goals.

Joint statements from the national science academies of the G7 nations were delivered today to the Italian government in advance of the G7 Summit to be held in Taormina, Italy, at the end of May.

Addressing cybersecurity attack concerns raised by generative AI, Smith said that there will be an increasing number of organisations and governments that will use the technology to develop cybersecurity threats.

Despite the noise around AI in the market right now, it is going to take time for companies to develop and adapt to the technology, Kalra said. On the business front, the company expects to fair well despite the challenging global environment and continue on its plan to expand in Europe and Asia Pacific while continuing the North America focus.

The organic snacks also has its sights set on increased national distribution.

Global Organics is proud to recognize its longtime partner, Natíve, for becoming the first Regenerative Organic Certified (ROC) sugar producer. 

The food solutions firm has lifted its 2025 regenerative agriculture goal to 5m acres.

Cheez-It, Club crackers to be sold with regenerative wheat.

An R&D expert from the sugar company shares insights on how the sustainable farming practice can benefit food producers, and the planet.

Generative AI, a subset of AI that can produce human-like content, has emerged as a pivotal tool in enhancing workplace safety.

Ravi Tandon has found success as an Associate Director at HCLTech

Regenerative Medicine is the future of medicine and has made excellent natural pain treatment advances with arthritis. Patients don't have to wait until the pain is unbearable, or surgery is the last option to get relief.

Innovative platelet-rich plasma (PRP) injections help treat patients in the Charlotte NC area for painful joint conditions.

50% of Motiva AI R&D now dedicated to Responsible AI

Regenerative Orthopedics & Sports Medicine (ROSM), a leader in non-surgical treatments for orthopedic conditions, is excited to announce the relocation of its Columbia, MD office to a new, state-of-the-art facility, as of August 26, 2024.

Generative AI seems to be everywhere right now, but what do you actually need to know? HBR IdeaCast is cutting through the noise in the special series How Generative AI Changes Everything. How will this new technology upend workforce productivity? What impact will it have on creativity and innovation? How can you build an internal culture that uses generative artificial intelligence and adopt it effectively in your organization? What could it mean for your company's strategy? Hosted by HBR editor in chief Adi Ignatius and HBR editor Amy Bernstein, you'll hear directly from the business leaders at the leading edge, as well as experts, who in some cases are questioning the ethics and speed of this rollout. If you want to understand what this technology means for your organization and how you can lead effectively, listen every Thursday in May in the HBR IdeaCast feed, after the regular Tuesday episode.

How Generative AI Changes Everything is a special series from HBR IdeaCast. Each week, HBR editor in chief Adi Ignatius and HBR editor Amy Bernstein host conversations with experts and business leaders about the impact of generative AI on productivity, creativity and innovation, organizational culture, and strategy. The episodes publish in the IdeaCast feed each Thursday in May, after the regular Tuesday episode. Generative artificial intelligence is grabbing headlines with the widespread public excitement over tools like ChatGPT. And early academic research shows significant productivity gains in written communications, customer service, market research, computer coding, and professional analysis such as legal work. Meanwhile, the technology is rapidly evolving and getting better the more people use it. As a leader, it’s hard to stay ahead of the developments. In this episode, How Generative AI Changes Productivity, Amy Bernstein speaks with Karim Lakhani, a professor at Harvard Business School and a coauthor of the book Competing in the Age of AI: Strategy and Leadership When Algorithms and Networks Run the World. They discuss initial productivity gains for individuals from the technology, how that will scale across a workforce, and the pressing challenges facing organizational leaders.

From prehistoric cave paintings to an inventor’s Eureka moment, creativity has always been described as a particularly human trait. But something strange can happen with generative artificial intelligence. Your ideas can take shape far faster. You also get ideas that you might never have imagined on your own. So, who is the creator here? What is creative work in the era of generative AI? What is innovation in this emerging world? In this episode, How Generative AI Changes Creativity, Adi Ignatius speaks with video artist and consultant Don Allen Stevenson III about how generative AI is disrupting creative work and the creative industry. Then Ignatius speaks to two innovation researchers, Jacqueline Ng Lane and David De Cremer, about changes to the creative process within organizations. Lane is a professor at Harvard Business School. De Cremer is a professor at the National University of Singapore Business School and a coauthor of the HBR article “How Generative AI Could Disrupt Creative Work.” How Generative AI Changes Everything is a special series from HBR IdeaCast. Each week, HBR editor in chief Adi Ignatius and HBR editor Amy Bernstein host conversations with experts and business leaders about the impact of generative AI on productivity, creativity and innovation, organizational culture, and strategy. The episodes publish in the IdeaCast feed each Thursday in May, after the regular Tuesday episode. And for more on ethics in the age of AI, check out HBR’s Big Idea on implementing the new technology responsibly.

Read just about any business history and you realize just how much a firm’s success depends on its culture. Without the right culture, you can't have successful innovation. You can't compete successfully. You can't thrive over the long term. So, if you want to lead your organization into a future that features generative artificial intelligence, you need to build the right culture for it. In this episode, How Generative AI Changes Organizational Culture, HBR editor Amy Bernstein speaks to two experts, Nitin Mittal and Tsedal Neeley, about how to adopt generative AI effectively and ethically within your organization. Mittal leads Deloitte’s global AI business and cowrote the book All-in On AI: How Smart Companies Win Big with Artificial Intelligence. Neeley is a professor at Harvard Business School and wrote the HBR article “8 Questions About Using AI Responsibly, Answered.” They discuss the risks, challenges, and emerging best practices of adapting organizational culture to generative AI. How Generative AI Changes Everything is a special series from HBR IdeaCast. Each week, HBR editor in chief Adi Ignatius and HBR editor Amy Bernstein host conversations with experts and business leaders about the impact of generative AI on productivity, creativity and innovation, organizational culture, and strategy. The episodes publish in the IdeaCast feed each Thursday in May, after the regular Tuesday episode. And for more on ethics in the age of AI, check out HBR’s Big Idea on implementing the new technology responsibly.

Strategy is about making the future happen, not just reacting to it, according to author Gary Hamel. And with generative artificial intelligence, senior leaders suddenly wield an awesome new tool to change the fortunes of their organizations. The promise of generative AI is more than just a sweet hack to boost productivity and streamline operations. Its deeper potential lies in companies that rethink what they do and conjure brand-new, AI-first products and services. Simply put, generative AI is blasting open new strategic paths to create novel business opportunities, even as it brings serious risks and heightened competition. In this episode, How Generative AI Changes Strategy, HBR editor in chief Adi Ignatius speaks to Microsoft’s head of strategy Chris Young and Harvard Business School professor Andy Wu. They lay out the technology, its emerging value chains, and its main providers. They also break down the key choices and tradeoffs that large and small companies alike will be making in this fast-changing market. This is the fourth and final episode in the special series How Generative AI Changes Everything. Each week, HBR editor in chief Adi Ignatius and HBR editor Amy Bernstein have been hosting conversations with experts and business leaders about the impact of generative AI. Find those episodes on the impact on productivity, creativity, and organizational culture in the HBR IdeaCast feed. And for more on ethics in the age of AI, check out HBR’s Big Idea on implementing the new technology responsibly.

Thanks to generative AI, content creation has become one of the most important trends in today’s world, with a completely new approach. It is revolutionizing the creative field in many different ways, from advertising to marketing to automated newspapers and magazines. Users of this technology must note its opportunities and problems. This blog discusses generative...

The post The Impact of Generative AI on Content Creation appeared first on noupe.

Event Begins: Wednesday, November 13, 2024 12:00pm
Location: Off Campus Location
Organized By: Information and Technology Services (ITS)

This workshop is designed to equip faculty with the necessary skills and knowledge to begin integrating Generative Artificial Intelligence into the classroom setting and considering its impact on students and instructions. Suggestions for discussing GenAI with students and guidance on writing a GenAI syllabus statement are explored in this workshop. This workshop also offers ideas for designing assignments in a GenAI era, ranging from (re)designing assignments to integrating GenAI into assignments. U-M GPT demonstrations will be included in this workshop.

Recommended Prerequisites:
Generative AI Basics [https://academictechnology.umich.edu/get-help/training/instructional-support/workshops/133]

Register: https://ttc.iss.lsa.umich.edu/ttc/sessions/generative-ai-in-the-classroom-11-13-24-2/

Workshop Outline:
- Can GenAI complete my assessment? How will GenAI affect my courses?
- Talking about GenAI with students
- GenAI syllabus statements
- Designing assignments in a GenAI era
- Resources and Support

Topics: Generative AI
Level: Beginner

Trainers: Monica Hickson and Jennifer Love

Discovery may propel advances in regenerative medicineTORONTO, ON – Consider the relationship between an air traffic controller and a pilot. The pilot gets the passengers to their destination, but the air traffic controller decides when the plane can take off and when it must wait. The same relationship plays out at the cellular level in […]

Evolving AI technology is becoming an important business tool for personalizing customer experience, analyzing data, and much more.

Itamar Friedman, the CEO and co-founder of CodiumAI, speaks with host Gregory M. Kapfhammer about how to use generative AI techniques to support automated software testing. Their discussion centers around the design and use of Cover-Agent, an open-source implementation of the automated test augmentation tool described in the Foundations of Software Engineering (FSE) paper entitled “Automated Unit Test Improvement using Large Language Models at Meta“ by Alshahwan et al. The episode explores how large-language models (LLMs) can aid testers by automatically generating test cases that increase the code coverage of an existing testing suite. They also investigate other automated testing topics, including how Cover-Agent compares to different LLM-based tools and the strengths and weaknesses of using LLM-based approaches in software testing.